Update on Biologics for Psoriasis in Clinical Practice

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Biologics have transformed psoriasis management.
• Moderate to severe psoriasis requires effective, long-term treatment options.

Purpose of the Study:

• To review recent Phase 3 clinical trial data (May 2020-Feb 2021) on biologic therapies for psoriasis.
• To provide clinicians with updated information on biologic performance, focusing on efficacy and safety.

Main Methods:

• Systematic review of 8 Phase 3 clinical trials.
• Analysis of data on IL-17A and IL-23 inhibitors.
• Evaluation of skin clearance, time to clearance, loss of response, relapse, and adverse events.

Main Results:

• US Food and Drug Administration-approved biologics demonstrate durable skin clearance.
• Efficacy is maintained despite comorbidities and treatment interruptions.
• IL-17A and IL-23 inhibitors show promising results in recent trials.

Conclusions:

• Current biologics provide sustained skin clearance for moderate to severe psoriasis.
• Understanding treatment-emergent adverse events is crucial for clinical practice.
• Recent data support the continued use and development of IL-17A and IL-23 inhibitors.